Ozon Pharmaceuticals reported for 9 months of 2024 by RAS

Ozone Pharmaceuticals' RAS net profit for 9 months of 2024 amounted to ₽1.51 billion, up 49.5% from ₽1.01 billion in the previous year. Revenue increased 58.7% to ₽1.65 billion compared to ₽1.04 billion a year earlier.